Press Release SYGNIS to Present its Innovative TruePrime™ Technology to Next Generation Sequencing Experts at VIB’s internationally renowned Tools and Technologies Meeting Madrid, Spain and Heidelberg, Germany, January 14th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced it will present its revolutionary novel multi displacement amplification (MDA) technology TruePrime™ to established experts in the field of next generation sequencing (NGS) at VIB’s Meeting “Revolutionizing Next-Generation Sequencing: Tools and Technologies” on January 15th, during the afternoon Parallel session 2 at 4:35 PM in the Kinepolis in Leuven, Belgium. This highly recognized conference is one of the key platforms for scientific players in the field of next generation sequencing worldwide. A major challenge for next generation sequencing applications is the limited amount of DNA available, especially when working with single or a few cells gained from, for example, biopsies in cancer research. Based on the recently discovered primase TthPrimPol, SYGNIS’ TruePrime™ technology stands for a revolutionary change in the way the amount of DNA or RNA in a sample can be amplified. While the current gold standard in MDA needs short pieces of DNA (“oligonucleotides”) to start off whole genome amplification, TruePrime™ does not need any synthetic random primers. Professor Dr. Armin Schneider, Senior Vice President Research at SYGNIS commented: “We are very proud and excited about the opportunity to introduce our next generation multiple displacement DNA amplification technology to such a selected group of experts. I am very much looking forward to discussing the outstanding advantages and the superior results that researchers can achieve when using our TruePrime™ MDA technology.” More information about the VIB Meeting “Revolutionizing Next Generation Sequencing: Tools and Technologies” can be found under: http://www.vibconferences.be/event/revolutionizing-next-generation-sequencing-tools-andtechnologies. The Company is currently developing a complete range of DNA and RNA amplification kits based on its proprietary TruePrime™ MDA technology. The first product for whole genome amplification from single cells is expected to be launched this month. Madrid, España/Heidelberg, Alemania SYGNIS Pharma AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Alemania, www.sygnis.de, Tel.: +49-6221-454-6, Fax: +49-6221-454-700 For further information please contact: SYGNIS AG Pilar de la Huerta CEO/CFO Phone: +34 91 192 36 50 Email: [email protected] MC Services AG Raimund Gabriel Managing Partner Phone: +49 89 210228 30 Email: [email protected] About SYGNIS AG: www.sygnis.com Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and is currently developing its own TruePrime™ product line based on its proprietary PrimPol technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification is expected to be launched in January 2015. ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.### Madrid, España/Heidelberg, Alemania SYGNIS Pharma AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Alemania, www.sygnis.de, Tel.: +49-6221-454-6, Fax: +49-6221-454-700